Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER vs AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Travasol 4.25% in Dextrose 15% is a combination of amino acids and dextrose used for parenteral nutrition. Amino acids provide substrates for protein synthesis, while dextrose provides a source of calories. The mechanism involves intravenous administration bypassing the gastrointestinal tract to deliver nutrients directly into the bloodstream, supporting tissue repair, growth, and metabolic functions.
Provides essential amino acids and histidine for protein synthesis in patients unable to tolerate oral or enteral nutrition, supporting nitrogen balance and tissue repair. The amino acids are utilized for anabolic processes and metabolic pathways.
Parenteral nutrition for patients unable to obtain adequate nutrition orally or enterally,Adjunct to oral or enteral nutrition when intake is insufficient,Metabolic support in catabolic states such as major surgery, trauma, or burns
Treatment of uremic patients undergoing dialysis who require essential amino acid supplementation,Nutritional support in patients with renal insufficiency or failure where nonessential nitrogen sources are contraindicated
Intravenous infusion; typical adult dose is 500 m L to 1000 m L per day, administered at a rate of 200 m L/hour, adjusted based on metabolic and fluid needs.
Intravenous infusion: 500 m L of 5.2% solution (26 g amino acids) over 8-12 hours daily, providing 0.8-1.2 g/kg/day of amino acids depending on metabolic needs.
Not applicable as a single entity; components have intrinsic half-lives. Amino acids: rapid distribution (minutes), with terminal elimination of metabolites (e.g., urea) ~4-8 hours. Dextrose: half-life ~1-2 hours in steady state.
Approximately 2-4 hours for most essential amino acids; clinical context: rapid clearance necessitates continuous infusion for stable plasma levels.
The amino acids in Travasol are metabolized via various pathways including transamination, deamination, and urea cycle in the liver and other tissues. Dextrose undergoes glycolysis and oxidative phosphorylation to produce ATP.
Amino acids are metabolized via transamination, deamination, and incorporation into proteins. Hepatic and renal pathways involved in nitrogen disposal and urea cycle.
TRAVASOL 4.25% IN DEXTROSE 15% (amino acids and dextrose) is a parenteral nutrition solution. Amino acids are metabolized to urea, which is excreted renally; dextrose is metabolized to CO2 and water. No significant biliary/fecal elimination.
Renal: >95% as amino acids and metabolites; negligible biliary/fecal.
Amino acids: minimal to no protein binding (<10%). Dextrose: not protein bound.
Minimal (<10%) for most amino acids; not significantly protein-bound.
Total body water distribution: ~0.55 L/kg for amino acids; dextrose distributes in extracellular fluid (~0.2 L/kg).
Approximately 0.2-0.4 L/kg total body water; reflects distribution primarily into extracellular fluid.
IV: 100% bioavailability; not administered orally or via other routes.
Intravenous: 100%.
In acute kidney injury or chronic kidney disease with GFR <30 m L/min, reduce volume and rate; monitor for electrolyte imbalances; consider avoidance in severe renal impairment.
For GFR < 30 m L/min: reduce dose to 0.5-0.8 g/kg/day; for GFR < 15 m L/min: 0.3-0.5 g/kg/day; avoid if severe untreated uremia.
No specific Child-Pugh based adjustments; use with caution in severe hepatic encephalopathy; monitor ammonia levels.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25-50%; Child-Pugh C: contraindicated due to risk of hepatic encephalopathy.
Dose based on weight: 2 to 6 g/kg/day of amino acids and 15 g/kg/day of dextrose; start at 2 g/kg/day of amino acids and titrate; typical infusion rate 100-200 m L/kg/day.
Infants and children: 1-2 g/kg/day as continuous infusion; neonates: 0.5-1 g/kg/day, titrated to metabolic response.
Start at lower infusion rates (e.g., 100 m L/hour); monitor fluid balance, renal function, and electrolytes; reduce total volume to avoid fluid overload.
Start at 0.6-0.8 g/kg/day; monitor renal function and protein tolerance; adjust for comorbidities like renal impairment or heart failure.
None
Not for intravenous infusion. For oral or enteral use only. Do not administer parenterally.
Do not administer if solution is discolored or contains particulate matter,Use with caution in patients with renal impairment, hepatic failure, or metabolic disorders,Monitor fluid and electrolyte balance, blood glucose, and acid-base status,Risk of infections related to catheter use,Rebound hypoglycemia may occur upon abrupt discontinuation
Monitor serum electrolytes, BUN, and ammonia levels; risk of hyperammonemia in hepatic impairment,Use with caution in patients with metabolic acidosis or fluid overload,May cause gastrointestinal intolerance; adjust rate of administration
Hypersensitivity to any component,Inborn errors of amino acid metabolism,Severe hyperglycemia or hyperosmolar state,Severe electrolyte disturbances,Severe hepatic or renal failure
Hypersensitivity to any component,Phenylketonuria (contains phenylalanine),Severe hepatic failure with hyperammonemia
No oral intake restrictions specific to this formulation as it is for parenteral use. However, if transitioning to oral feeding, coordinate with dietitian to avoid electrolyte imbalances or overfeeding.
No specific food interactions. Patients should follow prescribed dietary protein restrictions if indicated (e.g., in hepatic encephalopathy). Avoid alcohol as it may worsen liver function.
No expected increase in fetal malformation risk; amino acids and dextrose are endogenous nutrients. However, electrolyte disturbances or hyperglycemia may occur and can affect fetal development. First trimester: theoretical risk from metabolic derangements. Second and third trimesters: fetal growth and metabolic monitoring recommended.
Amino acid solutions like Aminess 5.2% are essential for fetal development. No teratogenic effects reported; however, use only if clearly needed as maternal nutritional status directly impacts fetal outcomes.
Components are normal blood constituents and are transferred into breast milk in small amounts. Not expected to cause adverse effects in breastfed infants. M/P ratio not established.
No data available on milk concentrations. Essential amino acids are normal components of breast milk. Use with caution; benefits likely outweigh risks in malnourished mothers.
Increased plasma volume and renal clearance in pregnancy may necessitate higher infusion rates to maintain adequate nutrition; individualize based on clinical response and laboratory parameters.
Pregnancy increases plasma volume and glomerular filtration rate, potentially altering pharmacokinetics. Monitor clinical response and consider dose adjustments based on metabolic demands; no specific dose adjustment guidelines available.
TRAVASOL 4.25% IN DEXTROSE 15% is a high-osmolarity parenteral nutrition solution (approximately 1700 m Osm/L). Must be administered via central venous line to avoid thrombophlebitis. Monitor serum glucose, electrolytes, renal function, and liver enzymes frequently. Risk of hyperglycemia, especially in stressed patients; consider insulin coverage. Do not use as a peripheral line solution due to high osmolarity.
Monitor serum ammonia levels in patients with hepatic impairment as essential amino acids may exacerbate hyperammonemia. Use with caution in fluid-restricted patients due to high volume load. Ensure adequate non-protein calories to promote protein synthesis and prevent amino acid catabolism. Do not administer simultaneously with blood products via same IV line.
This solution is given through a large vein in your chest, not a small vein in your arm.,You may need regular blood tests to check your blood sugar, kidney function, and mineral levels.,Report any signs of infection at the catheter site, such as redness, swelling, or pain.,Tell your healthcare provider if you feel unusually thirsty, urinate frequently, or have blurred vision.,Do not stop the infusion suddenly without medical advice.
This solution provides essential amino acids to support protein synthesis when you cannot eat enough protein.,It is given intravenously; report any burning, pain, or swelling at the IV site.,Your blood may be monitored for ammonia and electrolyte levels during treatment.,Inform your healthcare provider if you have liver disease, diabetes, or fluid restrictions.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER vs AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE, answered by our medical review team.
TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER is a Parenteral Nutrition Solution that works by Travasol 4.25% in Dextrose 15% is a combination of amino acids and dextrose used for parenteral nutrition. Amino acids provide substrates for protein synthesis, while dextrose provides a source of calories. The mechanism involves intravenous administration bypassing the gastrointestinal tract to deliver nutrients directly into the bloodstream, supporting tissue repair, growth, and metabolic functions.. AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is a Parenteral Nutrition Solution that works by Provides essential amino acids and histidine for protein synthesis in patients unable to tolerate oral or enteral nutrition, supporting nitrogen balance and tissue repair. The amino acids are utilized for anabolic processes and metabolic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER and AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE depend on the specific clinical indication. These are both Parenteral Nutrition Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER is: Intravenous infusion; typical adult dose is 500 m L to 1000 m L per day, administered at a rate of 200 m L/hour, adjusted based on metabolic and fluid needs.. The standard adult dose of AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is: Intravenous infusion: 500 m L of 5.2% solution (26 g amino acids) over 8-12 hours daily, providing 0.8-1.2 g/kg/day of amino acids depending on metabolic needs.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER and AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER is classified as Category C. No expected increase in fetal malformation risk; amino acids and dextrose are endogenous nutrients. However, electrolyte disturbances or hyperglycemia may occur and can affect feta. AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is classified as Category C. Amino acid solutions like Aminess 5.2% are essential for fetal development. No teratogenic effects reported; however, use only if clearly needed as maternal nutritional status dire. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.